The DNA microarray market is witnessing steady growth due to the rising demand for advanced genomic research, personalized medicine, and early disease diagnosis. The increasing prevalence of cancer, ...

Global Market OverviewThe Global Non-Invasive Prenatal Testing (NIPT) Market is projected to expand at a CAGR of 16% by 2029, ...

A slippery droplet microarray enables parallel 3D bioprinting of separated, immersed hydrogel models, cutting array ...

The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...

A DNA index cutoff ≥1.10 delivered excellent discrimination for HHD (AUC 0.947) with high sensitivity and near-rule-out performance when negative (NPV 99.1%). Karyotype failure occurred in 25.2%, and ...

Gene expression analysis helps uncover how cells function, adapt, and contribute to disease. Techniques from microarray preprocessing to advanced single-cell proteomics offer complementary insights ...

Cytogenetics is rapidly advancing with innovations that merge traditional chromosome analysis with automation, AI, and high-throughput genomic tools. These developments are improving speed, accuracy, ...

OGM Can Resolve Previously Unresolved Rare Disease CasesOGM Can Serve as a Gold Standard Technique for Characterization of ...

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up ...

Mechanistic insights on how NRG4 suppresses obesity-driven breast cancer metastasis Breast cancer remains a leading cause of ...

For the quarter ended March 2026, Illumina (ILMN) reported revenue of $1.09 billion, up 4.8% over the same period last year. EPS came in at $1.15, compared to $0.97 in the year-ago quarter. The ...